Navigation Links
NicOx Announces TOPIGEN Initiates Phase 2 Proof of Concept Study in COPD for TPI 1020
Date:11/20/2007

SOPHIA ANTIPOLIS, France, Nov. 20 /PRNewswire/ -- NicOx S.A. (Eurolist: COX) today announced that TOPIGEN Pharmaceuticals Inc. has dosed the first patients in a phase 2 proof of concept study for TPI 1020 in Chronic Obstructive Pulmonary Disease (COPD) - see TOPIGEN press release attached. This new study is expected to provide the first assessment of TPI 1020's potential activity in COPD. TPI 1020 is a new chemical entity and novel anti- inflammatory licensed by TOPIGEN from NicOx for COPD and other respiratory disorders.

This new clinical study follows the recent announcement of promising top- line results from a phase 2a study in asthmatic smokers, where TPI 1020 showed a good safety and tolerability profile, in addition to certain anti- inflammatory effects which could be potentially beneficial in COPD (see press release of September 11, 2007). COPD is a respiratory disease caused by chronic inflammation of the lungs and bronchi and represents the third-leading cause of death in the United States (see NOTE).

Pascal Pfister, Chief Scientific Officer at NicOx, said: "We believe TPI 1020, which has a novel mechanism of action due to NicOx technology, could have the potential to bring real benefits to people suffering from COPD, based on data that has been observed in preclinical studies and the recently reported asthmatic smoker safety study. The progression of the TPI 1020 program is a testament to TOPIGEN's expertise in the respiratory therapeutic area, as well as the broad potential of NicOx' technology, and we see this collaboration as a validation of our strategy of partnering with leading biopharmaceutical companies outside our key therapeutic domains. We look forward to the results of this phase 2 proof of concept study, which should provide an important assessment of the compound's activity."

Under the terms of the agreement signed between NicOx and TOPIGEN in October 2005, TOPIGEN acquired the development and commercialization right
'/>"/>

SOURCE NicOx
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. NicOx Reports TOPIGEN to Advance TPI-1020 Into Phase 2 for COPD Following Promising Clinical Results
2. NicOx and Ferrer Present Promising Clinical and Preclinical Results in Dermatology
3. NicOx Naproxcinod ABPM Data Presented at American Heart Association
4. NicOx Naproxcinod Phase 3 Results Presented at American College of Rheumatology
5. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
6. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
7. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
8. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
9. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
10. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
11. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... , Jan. 22, 2015  Profil Institute for Clinical Research, ... and obesity, announced today a new textbook,  Translational Research ... by Springer, a leading global scientific publisher. ... illustrate techniques for use in early phase clinical studies ...
(Date:1/22/2015)... Jan. 22, 2015 Research and Markets ( ... "Infectious Disease Diagnostics Market by Product, Application, Technology, End ... their offering. , The infectious disease diagnostics ... to reach $18,156.2 million by 2019 from $12,422.8 million ...
(Date:1/22/2015)... and Markets ( http://www.researchandmarkets.com/research/w25xpc/allergy ) has announced the ... Product & by End User - Global Forecast to 2019" ... allergy diagnostics market is valued at $1,228.58 million in 2014 ... to reach $2,230.72 million by 2019. Allergy diagnostics is used ...
Breaking Medicine Technology:New Textbook "Translational Research Methods for Diabetes, Obesity and Cardiometabolic Drug Development" Provides Critical Review Of Current And Emerging Clinical Investigation Methods 2New Textbook "Translational Research Methods for Diabetes, Obesity and Cardiometabolic Drug Development" Provides Critical Review Of Current And Emerging Clinical Investigation Methods 3Global Infectious Disease Diagnostics (Instruments, Reagents, Services, Software) Market - Forecast to 2019 2Global Infectious Disease Diagnostics (Instruments, Reagents, Services, Software) Market - Forecast to 2019 3Global Allergy Diagnostics (Immunoassay Analyzer, Luminometer, Assay Kit, Consumables) Market - Forecast to 2019 2Global Allergy Diagnostics (Immunoassay Analyzer, Luminometer, Assay Kit, Consumables) Market - Forecast to 2019 3
... , ATLANTA, Nov. 6 GeoVax Labs, Inc. ... an Atlanta-based, biopharmaceutical company developing human vaccines for diseases ... agents, today announced its third quarter 2009 financial results ... President and Chief Executive Officer commented, "We are pleased ...
... PARIS, November 6 , ... Oral Agent Linezolid for the,Treatment of Multi-Resistant Staphylococcus Aureus ... speciality pharmaceutical company focused on the discovery and,development of ... microbial resistance, announces today that its most advanced oral,antibacterial ...
Cached Medicine Technology:GeoVax Labs, Inc. Provides Third Quarter 2009 Financial Results and Operational Update 2GeoVax Labs, Inc. Provides Third Quarter 2009 Financial Results and Operational Update 3GeoVax Labs, Inc. Provides Third Quarter 2009 Financial Results and Operational Update 4GeoVax Labs, Inc. Provides Third Quarter 2009 Financial Results and Operational Update 5GeoVax Labs, Inc. Provides Third Quarter 2009 Financial Results and Operational Update 6GeoVax Labs, Inc. Provides Third Quarter 2009 Financial Results and Operational Update 7GeoVax Labs, Inc. Provides Third Quarter 2009 Financial Results and Operational Update 8Novexel Starts Phase II Clinical Trial With NXL103 in Adults With Acute Bacterial Skin and Skin Structure Infections (ABSSSI) 2Novexel Starts Phase II Clinical Trial With NXL103 in Adults With Acute Bacterial Skin and Skin Structure Infections (ABSSSI) 3Novexel Starts Phase II Clinical Trial With NXL103 in Adults With Acute Bacterial Skin and Skin Structure Infections (ABSSSI) 4
(Date:1/22/2015)... 23, 2015 VogueQueen is a seasoned and ... and many designers are thrilled to have it lead the ... its new collection of prom dresses for the global market. ... the strategic vision and he focuses on continuing the goal ...
(Date:1/22/2015)... York, New York (PRWEB) January 22, 2015 ... http://www.vaginalmeshlawsuit2015.com/ ) in the U.S. District Court, Southern District of ... C.R. Bard, Inc. in that proceeding’s first bellwether trial. In ... request for a new trial after finding that C.R. Bard ...
(Date:1/22/2015)... over 20 years, Dr. David Cruz of Cruz Chiropractic Care ... just about every type of injury that can result from car ... twenty-plus years, the team at Doctors on Liens has ... doctor. With the combined breadth of experience between the ...
(Date:1/22/2015)... Weddingshe.com has added many trendy Champagne wedding dresses ... in the past three years. Today, the business announces a ... to the sales manager of the company, this is on ... This point can be reflected on the discounted wedding dresses ...
(Date:1/22/2015)... As interest in the value of spiritual support as ... Rev. Eric J. Hall , president and CEO of the ... the keynote speaker on January 27 at an international summit ... The conference, “Hope and Resilience: Innovative and Interdisciplinary Spiritual Care,” ...
Breaking Medicine News(10 mins):Health News:VogueQueen Unveils New Designs of Prom Dresses for 2015 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 3Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 4Health News:Industry Leading Chiropractor in Oceanside Joins the Doctors on Liens Network 2Health News:Weddingshe Announces A Special Offer On Its Popular Glamorous Wedding Dresses 2Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 2Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 3
... recent study that by actually allowing a stream of mild ... can stimulate a person’s mind helping him definitely to clearly ... would ordinarily be able to do. ,Neuroscientist Lisa Marshall ... study found that applying electrical stimuli to the brain scalp ...
... the faint hearted - there is a 1 in 300 chance ... doctor in England Sir Liam Donaldson has said in a cautionary ... of the WHO's campaign on the need for hospitals to address ... figures beat the chances of dying in an aircrash hollow , ...
... York - Dr. Ragnfrid H. Nordbo, of the Norwegian Institute ... of people// suffering anorexia nervosa, a form of eating disorder, ... deal of importance to self-starvation, which has its roots in ... treatment measures that do not take cognizance of the significance ...
... technique used in treating cancer , in which antibodies ... patients.// These antibodies target and destroy cancer cells inside ... main advatage of this treatment is that it is ... mice showed that this approach could be used to treat ...
... famous Pulitzer Prize-winning novelist, passed away today at Martha's ... died of pneumonia at Martha's Vineyard Hospital. ... class and his own guilt that made him write ... of Nat Turner,"that won him the Pulitzer among protests. ...
... alive. He is 7 feet, 8.95 inches tall.// The Guinness Day ... will be sent to Brazil to participate in the celebrations. ... Records, 2007, which he will autograph in Rio de Janeiro. He ... famous Avenida Paulista. ,Xi is a herdsman by profession ...
Cached Medicine News:Health News:A New Option For AIDS Treatment - Radioimmunotherapy 2
Hudson Downs hand drill....
The Greenberg retractor and handrest is a versatile, three level system offering efficient space planning, whereby each level has an assigned surgical task....
Binocular operation microscope with innovative mechanism for smooth operation....
... the finest integration of Olympus' ... optics, digital imaging, electronics, and ... microscope. The surgical microscope incorporates ... surgeon an unprecedented degree of ...
Medicine Products: